Allogene Therapeutics

+$0.20 (+0.91%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALLO and other ETFs, options, and stocks.

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.

CEO
David D. Chang
Employees
265
Headquarters
South San Francisco, California
Founded
2017

ALLO Key Statistics

Market Cap
3.42B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
563.01K
High Today
$22.93
Low Today
$21.56
Open Price
$21.60
Volume
741.90K
52 Week High
$44.92
52 Week Low
$21.10

ALLO Earnings

-$0.68
-$0.54
-$0.39
-$0.25
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
-$0.55 per share
Actual
-$0.53 per share
Replay Earnings Call
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure